NASDAQ: ELDNEledon Pharmaceuticals Inc Stock
$3.95+0.05 (+1.28%)
Updated Jul 2, 2026
ELDN Price
$3.95
Fair Value Price
$0.27
Market Cap
$304.89M
52 Week Low
$1.35
52 Week High
$4.60
P/E
-5.13x
P/B
6.81x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$79.50M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.03
Operating Cash Flow
-$69M
Beta
0.82
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ELDN Overview
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELDN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELDN
Ranked#440 of 463
Ranked#440 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important ELDN news, forecast changes, insider trades & much more!
ELDN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELDN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELDN ($3.95) is overvalued by 1,358.26% relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELDN ($3.95) is not significantly undervalued (1,358.26%) relative to our estimate of its Fair Value price of $0.27 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELDN due diligence checks available for Premium users.
Valuation
ELDN fair value
Fair Value of ELDN stock based on Discounted Cash Flow (DCF)
Price
$3.95
Fair Value
$0.27
Overvalued by
1,358.26%
ELDN ($3.95) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELDN ($3.95) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELDN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELDN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.13x
Industry
17.59x
Market
8.54x
ELDN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.81x
Industry
5.6x
ELDN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELDN's financial health
Profit margin
Revenue
$0.0
Net Income
-$39.0M
Profit Margin
0%
ELDN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$146.7M
Liabilities
$46.2M
Debt to equity
1.03
ELDN's short-term assets ($113.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELDN's short-term assets ($113.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELDN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ELDN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.6M
Investing
$6.0M
Financing
$0.0
ELDN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELDN vs Biotech Stocks
Eledon Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.